Evidence map›Paper›PMID 37325245›Full record

ArticleBlood cell therapy2020

Treatment of relapsed acute leukemia by Ara C plus donor lymphocyte infusion using CD34＋ cells reserved at the time of allogeneic transplantation.

Lee Yj, Back Dw, Cho Hc, Moon Jh, Sohn Sk

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cell therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 68% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Lee YjDivision of Hematology-Oncology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea.
Back DwDivision of Hematology-Oncology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea.
Cho HcDivision of Hematology-Oncology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea.
Moon JhDivision of Hematology-Oncology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea.
Sohn SkDivision of Hematology-Oncology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea.
Kyungpook National University Hospital · KRKyungpook National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, there is no standard therapy available for relapsed acute leukemia after allogeneic hematopoietic cell transplantation (allo-HCT). In this study, we evaluated the efficacy of cytoreduction with cytarabine followed by granulocyte colony-stimulating factor (G-CSF)-primed donor lymphocyte infusion (DLI) for patients with acute leukemia who relapsed after allo-HCT. We retrospectively reviewed 255 patients who had received allo-HCT for acute leukemia/myelodysplastic syndrome. Patients were divided into two groups based on the CD34＋ cell dose they received during the initial transplantation; patients in the lower CD34＋ group received a dose lower than 6×10

Indexed as

Acute leukemiaDonor lymphocyte infusionGranulocyte colony-stimulating factorHematopoietic stem cell transplantationRecurrence

Identifiers

PMID37325245
PMCPMC10261720
OpenAlexW4254210630

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.